Researchers at The University of Texas MD Anderson Cancer Center have identified seven distinct cellular environments within diffuse large B-cell lymphoma (DLBCL) tumors. These findings point to new avenues for developing therapies that harness the body’s own immune powers to fight cancer.

Researchers have discovered a novel way to retrain neutrophils—the body’s first responders—to directly attack aggressive breast cancer cells, offering new hope to patients unresponsive to current immunotherapies.

Promising advances in immunotherapy may allow some cancer patients to bypass chemotherapy, radiation, and surgery. New clinical trial findings reported by Dr. Jon LaPook suggest a groundbreaking shift in cancer treatment, offering renewed hope to many.